
Blogs
Two views, one decision: Inside HAS’ approach to early access for Ojemda™ in France
Written by Johann Sanseau, Associate Consultant: [email protected] Haute Autorité de Santé (HAS) recently granted post-Marketing Authorisation (MA) early access (accès précoce) to Ojemda™ (tovorafenib) for